DelveInsight's “Endometriosis Pipeline Insight 2026” report provides comprehensive insights into the endometriosis pipeline landscape, covering 20+ companies and 22+ pipeline drugs. The report includes detailed profiles of clinical- and nonclinical-stage pipeline therapies, along with therapeutic assessments by product type, development stage, route of administration, and molecule type. It also highlights inactive pipeline products and key developments shaping the treatment landscape.

Request a sample and discover the recent advances in Endometriosis Drugs:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Endometriosis Pipeline Report

  • In August 2026, Medicus Pharma received UAE regulatory clearance to initiate its Phase IIa PRECISION-E2 trial evaluating teverelix in women with moderate-to-severe endometriosis using a genomics-guided precision medicine approach.
  • In August 2026, Sunshine Biopharma announced Canadian approval for its 2 mg generic dienogest tablets for pelvic pain associated with endometriosis, with commercial availability expected by the end of 2026.
  • DelveInsight's Endometriosis Pipeline report identifies a robust development landscape, with 20+ active companies working on 22+ pipeline therapies.
  • Leading endometriosis companies include Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.
  • Promising endometriosis therapies include Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219, and others.

Find out more about Endometriosis Drugs:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Overview

Endometriosis is characterized by the presence of endometrial gland- and stroma-like lesions outside the uterus. These lesions can occur as peritoneal lesions, superficial implants, cysts, or deep infiltrating disease.

Although the definitive cause of endometriosis remains unclear, several hypotheses have been proposed regarding the development of endometriotic lesions. One potential mechanism involves retrograde menstruation, in which endometrial tissue flows through the fallopian tubes into the pelvic cavity. Retrograde flow, along with possible hematogenous or lymphatic circulation, may contribute to the implantation of endometrial tissue at ectopic sites.

Endometriosis Emerging Drugs

HMI-115: Hope Medicine (Nanjing) Co., Ltd.

HMI-115 is a first-in-class monoclonal antibody targeting the prolactin receptor (PRLR), for which Hope Medicine holds global rights. The candidate is being developed for multiple indications, including endometriosis and androgenic alopecia, as well as other chronic diseases.

HMI-115 has demonstrated favorable characteristics in animal models, including non-human primate models, as well as human safety data. The drug is currently in Phase III development for the treatment of endometriosis.

Merigolix: TiumBio

Merigolix (TU2670) is an oral GnRH antagonist designed to bind to pituitary receptors and suppress estradiol levels. Unlike GnRH agonists, which are generally administered through injections and can suppress sex hormones to menopausal levels, TU2670 is designed to provide oral administration while suppressing hormone levels to a therapeutic range.

This approach may help address treatment-related side effects and improve convenience. The mechanism may also support potential expansion into indications such as precocious puberty, in vitro fertilization, and infertility treatment.

Merigolix is currently being evaluated in Phase II clinical development for endometriosis.

Nibrozetone (RRx-001): EpicentRx

Nibrozetone, also known as RRx-001, is an investigational therapy with anti-inflammatory and antioxidant properties. Its mechanism includes the release of metabolites such as nitric oxide and other nitrogen-centered free radicals in hypoxic environments.

In non-hypoxic environments, RRx-001 has demonstrated anti-inflammatory and antioxidant activity through mechanisms involving the NLRP3 inflammasome and Nrf2 pathways. The therapy is currently in Phase I development for endometriosis.

What the Endometriosis Pipeline Report Provides

The Endometriosis Pipeline Insight report provides detailed analysis of the evolving therapeutic landscape, including:

  • Detailed insights into companies developing therapies for endometriosis and the therapies being developed by each company.
  • Assessment of therapeutic candidates across early-, mid-, and late-stage development.
  • Analysis of companies involved in targeted therapeutic development, including active and inactive, dormant, or discontinued projects.
  • Evaluation of pipeline therapies based on development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
  • Detailed analysis of company-company collaborations, company-academia collaborations, licensing agreements, and financing activities supporting future development.

Learn more about Endometriosis drug development opportunities:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Companies

The key companies active in the endometriosis pipeline include:

Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.

Endometriosis Pipeline by Route of Administration

The report provides a therapeutic assessment of pipeline therapies according to their route of administration. Products are categorized into:

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Endometriosis Pipeline by Molecule Type

Pipeline products are also categorized according to molecule type, including:

  • Recombinant fusion proteins
  • Small molecules
  • Monoclonal antibodies
  • Peptides
  • Polymers
  • Gene therapies

Stay informed about emerging Endometriosis treatments:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Scope of the Endometriosis Pipeline Report

  • Coverage: Global
  • Key Endometriosis Companies: Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.
  • Key Endometriosis Therapies: Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219, and others.
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Dive deeper into emerging Endometriosis Treatments:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Endometriosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Endometriosis: DelveInsight's Analytical Perspective
  7. Late-Stage Products (Phase III)
  8. Estelle: Gedeon Richter
  9. Mid-Stage Products (Phase II)
  10. GenSci048: Changchun GeneScience Pharmaceutical Co., Ltd.
  11. Early-Stage Products (Phase I)
  12. Preclinical and Discovery-Stage Products
  13. MP137P: NETRIS Pharma
  14. Inactive Products
  15. Endometriosis Key Companies
  16. Endometriosis Key Products
  17. Endometriosis: Unmet Needs
  18. Endometriosis: Market Drivers and Barriers
  19. Endometriosis: Future Perspectives and Conclusion
  20. Endometriosis Analyst Views
  21. Endometriosis Key Companies
  22. Appendix

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry professionals and expertise across the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients worldwide.

DelveInsight provides comprehensive healthcare and pharmaceutical market research, pipeline intelligence, epidemiology, competitive intelligence, and consulting solutions designed to help life sciences companies understand evolving markets and identify emerging opportunities.

Contact Us

Kanishk

[email protected]